Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer

NCT07402473 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

50

Enrollment

OTHER

Sponsor class

Conditions

HER2-positive Early-stage Breast Cancer

Interventions

DRUG: Trastuzumab
DRUG: Pertuzumab
DRUG: Docetaxel
DRUG: Carboplatin

Sponsor

Rutgers, The State University of New Jersey